Urogen Pharma (NASDAQ:URGN) CFO Chris Degnan Sells 2,202 Shares of Stock

Urogen Pharma (NASDAQ:URGN) CFO Chris Degnan sold 2,202 shares of the business’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $36.69, for a total transaction of $80,791.38. Following the sale, the chief financial officer owned 4,561 shares in the company, valued at $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Urogen Pharma Trading Down 0.4%

Shares of NASDAQ:URGN opened at $36.83 on Friday. The company has a 50 day moving average of $43.82 and a 200-day moving average of $34.59. The firm has a market cap of $1.80 billion, a P/E ratio of -18.60 and a beta of 1.57. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $50.81.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. Equities research analysts forecast that Urogen Pharma will post -0.20 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a research note on Thursday, September 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Oppenheimer boosted their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Guggenheim raised their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.38.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds have recently modified their holdings of URGN. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma during the 2nd quarter worth about $66,000. Quantbot Technologies LP acquired a new position in shares of Urogen Pharma in the second quarter worth about $78,000. Glenmede Trust Co. NA acquired a new position in shares of Urogen Pharma in the first quarter worth about $189,000. Janus Henderson Group PLC purchased a new position in shares of Urogen Pharma in the first quarter worth approximately $343,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Urogen Pharma in the second quarter worth approximately $412,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.